B. Riley set a $6.00 price target on Biomerica (NASDAQ:BMRA) in a research report sent to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock. B. Riley also issued estimates for Biomerica’s Q1 2020 earnings at ($0.06) EPS, Q2 2020 earnings at ($0.08) EPS, Q3 2020 earnings at ($0.06) EPS, FY2020 earnings at ($0.27) EPS and FY2022 earnings at $0.75 EPS.
Shares of NASDAQ:BMRA remained flat at $$3.05 during trading on Tuesday. 18,294 shares of the stock were exchanged, compared to its average volume of 26,827. The firm’s fifty day moving average is $3.13 and its two-hundred day moving average is $2.67. The firm has a market cap of $27.79 million, a PE ratio of -11.73 and a beta of 1.45. Biomerica has a twelve month low of $1.60 and a twelve month high of $3.78.
Biomerica (NASDAQ:BMRA) last posted its quarterly earnings data on Friday, August 30th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $1.17 million during the quarter, compared to analyst estimates of $1.36 million. Biomerica had a negative net margin of 46.01% and a negative return on equity of 58.31%. Equities analysts expect that Biomerica will post -0.33 EPS for the current year.
A hedge fund recently bought a new stake in Biomerica stock. Susquehanna International Group LLP acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,688 shares of the company’s stock, valued at approximately $46,000. Susquehanna International Group LLP owned about 0.18% of Biomerica at the end of the most recent reporting period. Institutional investors and hedge funds own 1.24% of the company’s stock.
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.